These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 30360939)

  • 21. Distinct IL-4-induced gene expression, proliferation, and intracellular signaling in germinal center B-cell-like and activated B-cell-like diffuse large-cell lymphomas.
    Lu X; Nechushtan H; Ding F; Rosado MF; Singal R; Alizadeh AA; Lossos IS
    Blood; 2005 Apr; 105(7):2924-32. PubMed ID: 15591113
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cell-of-origin determined by both gene expression profiling and immunohistochemistry is the strongest predictor of survival in patients with diffuse large B-cell lymphoma.
    Abdulla M; Hollander P; Pandzic T; Mansouri L; Ednersson SB; Andersson PO; Hultdin M; Fors M; Erlanson M; Degerman S; Petersen HM; Asmar F; Grønbaek K; Enblad G; Cavelier L; Rosenquist R; Amini RM
    Am J Hematol; 2020 Jan; 95(1):57-67. PubMed ID: 31659781
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Microarray-based classification of diffuse large B-cell lymphoma.
    Poulsen CB; Borup R; Nielsen FC; Borregaard N; Hansen M; Grønbaek K; Møller MB; Ralfkiaer E
    Eur J Haematol; 2005 Jun; 74(6):453-65. PubMed ID: 15876249
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rewired NFκB signaling as a potentially actionable feature of activated B-cell-like diffuse large B-cell lymphoma.
    Knittel G; Liedgens P; Korovkina D; Pallasch CP; Reinhardt HC
    Eur J Haematol; 2016 Dec; 97(6):499-510. PubMed ID: 27526684
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Activating mutations affecting the NF-kappa B pathway and EZH2-mediated epigenetic regulation are rare events in primary mediastinal large B-cell lymphoma.
    Gebauer N; Hardel TT; Gebauer J; Bernard V; Merz H; Feller AC; Rades D; Biersack H; Lehnert H; Thorns C
    Anticancer Res; 2014 Oct; 34(10):5503-7. PubMed ID: 25275047
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Nodal versus extranodal diffuse large B-cell lymphoma: comparison of clinicopathologic features, immunophenotype and prognosis].
    Lu JB; Li XQ; Zhang PH; Zhou XY; Zhang TM; Li XM; Zhu XZ
    Zhonghua Bing Li Xue Za Zhi; 2007 Jul; 36(7):470-3. PubMed ID: 17845761
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunohistochemical subtyping of diffuse large B-cell lymphoma into germinal center B-cell and activated B-cell subtype, along with correlation of the subtypes with extranodal involvement, serum lactate dehydrogenase, and positron emission tomography scan-based response assessment to chemotherapy.
    Tyagi A; Abrari A; Khurana A; Tyagi S
    J Cancer Res Ther; 2022; 18(4):1129-1136. PubMed ID: 36149172
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Primary central nervous system lymphoma: Comprehension of cell-of-origin subtypes.
    Rao S; Epari S; Shet TM; Gujral S; Jain H; Bagal B; Senagar M; Shetty P; Moiyadi A; Goda JS; Gupta T
    Indian J Pathol Microbiol; 2023; 66(3):549-555. PubMed ID: 37530337
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [PROGNOSTIC ROLE OF NF-κB EXPRESSION IN DIFFUSE LARGE B-CELL LYMPHOMA SUBGROUPS].
    Škunca Z; Planinc-Peraica A
    Acta Med Croatica; 2015 Mar; 69(1):25-32. PubMed ID: 26606782
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Germinal center B-cell-like versus non-germinal center B-cell-like as important prognostic factor for localized nodal DLBCL.
    Habara T; Sato Y; Takata K; Iwaki N; Okumura H; Sonobe H; Tanaka T; Orita Y; Abd Al-Kader L; Asano N; Ennishi D; Yoshino T
    J Clin Exp Hematop; 2012; 52(2):91-9. PubMed ID: 23037624
    [TBL] [Abstract][Full Text] [Related]  

  • 31. BAFF-R is expressed on B-cell lymphomas depending on their origin, and is related to proliferation index of nodal diffuse large B-cell lymphomas.
    Takahata H; Ohara N; Ichimura K; Tanaka T; Sato Y; Morito T; Takata K; Kojima M; Kobata T; Yoshino T
    J Clin Exp Hematop; 2010; 50(2):121-7. PubMed ID: 21123970
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Comparative study of heterogeneity of extranodal and nodal diffuse large B cell lymphoma].
    Yin HF; Li T
    Beijing Da Xue Xue Bao Yi Xue Ban; 2007 Apr; 39(2):158-62. PubMed ID: 17440591
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Usefulness of immunohistochemistry in identification of prognostically important subgroups (GCB and ABC) in a heterogeneous group of diffuse large B-cell lymphomas--a review article.
    Jabłońska J; Jesionek-Kupnicka D
    Pol J Pathol; 2008; 59(3):121-7. PubMed ID: 19097355
    [TBL] [Abstract][Full Text] [Related]  

  • 34. FOXP1 protein overexpression is associated with inferior outcome in nodal diffuse large B-cell lymphomas with non-germinal centre phenotype, independent of gains and structural aberrations at 3p14.1.
    Hoeller S; Schneider A; Haralambieva E; Dirnhofer S; Tzankov A
    Histopathology; 2010 Jul; 57(1):73-80. PubMed ID: 20579129
    [TBL] [Abstract][Full Text] [Related]  

  • 35. FOXP1 suppresses immune response signatures and MHC class II expression in activated B-cell-like diffuse large B-cell lymphomas.
    Brown PJ; Wong KK; Felce SL; Lyne L; Spearman H; Soilleux EJ; Pedersen LM; Møller MB; Green TM; Gascoyne DM; Banham AH
    Leukemia; 2016 Mar; 30(3):605-16. PubMed ID: 26500140
    [TBL] [Abstract][Full Text] [Related]  

  • 36. ASB2 is a direct target of FLI1 that sustains NF-κB pathway activation in germinal center-derived diffuse large B-cell lymphoma.
    Sartori G; Napoli S; Cascione L; Chung EYL; Priebe V; Arribas AJ; Mensah AA; Dall'Angelo M; Falzarano C; Barnabei L; Forcato M; Rinaldi A; Bicciato S; Thome M; Bertoni F
    J Exp Clin Cancer Res; 2021 Nov; 40(1):357. PubMed ID: 34763718
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Stratifying diffuse large B-cell lymphoma patients treated with chemoimmunotherapy: GCB/non-GCB by immunohistochemistry is still a robust and feasible marker.
    Batlle-López A; González de Villambrosía S; Francisco M; Malatxeberria S; Sáez A; Montalban C; Sánchez L; Garcia J; González-Barca E; López-Hernández A; Ruiz-Marcellan MC; Mollejo M; Grande C; Richards KL; Hsi ED; Tzankov A; Visco C; Xu-Monette ZY; Cao X; Young KH; Piris MÁ; Conde E; Montes-Moreno S
    Oncotarget; 2016 Apr; 7(14):18036-49. PubMed ID: 26910115
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma.
    Dunleavy K; Pittaluga S; Czuczman MS; Dave SS; Wright G; Grant N; Shovlin M; Jaffe ES; Janik JE; Staudt LM; Wilson WH
    Blood; 2009 Jun; 113(24):6069-76. PubMed ID: 19380866
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High prevalence of the MYD88 mutation in testicular lymphoma: Immunohistochemical and genetic analyses.
    Oishi N; Kondo T; Nakazawa T; Mochizuki K; Tanioka F; Oyama T; Yamamoto T; Iizuka J; Tanabe K; Shibata N; Kirito K; Katoh R
    Pathol Int; 2015 Oct; 65(10):528-35. PubMed ID: 26388135
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Discriminant analysis and machine learning approach for evaluating and improving the performance of immunohistochemical algorithms for COO classification of DLBCL.
    Perfecto-Avalos Y; Garcia-Gonzalez A; Hernandez-Reynoso A; Sánchez-Ante G; Ortiz-Hidalgo C; Scott SP; Fuentes-Aguilar RQ; Diaz-Dominguez R; León-Martínez G; Velasco-Vales V; Cárdenas-Escudero MA; Hernández-Hernández JA; Santos A; Borbolla-Escoboza JR; Villela L
    J Transl Med; 2019 Jun; 17(1):198. PubMed ID: 31185999
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.